InvestorsHub Logo
Followers 833
Posts 119916
Boards Moderated 17
Alias Born 09/05/2002

Re: James salmon post# 16527

Friday, 03/24/2017 1:33:46 PM

Friday, March 24, 2017 1:33:46 PM

Post# of 108192
A negative vote in the House seems baked-in at this point. What concerns me as a biotech investor is that the inability to pass healthcare legislation could make it harder for Congress to pass US corporate-tax reform, due to the peculiarities of the Congressional budgeting process.

If there are diminished prospects for US corporate-tax reform, much of the gain in the broad stock market (including many drug/biotech stocks) since the US presidential election could evaporate.

https://twitter.com/DewDiligence/status/844589886661365761

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News